Fulltext

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer

Kanesvaran R 1 , Castro E 2 , Wong A 3 , Fizazi K 4 , Chua MLK 5 , Zhu Y 6 Show all authors , Malhotra H 7 , Miura Y 8 , Lee JL 9 , Chong FLT 10 , Pu YS 11 , Yen CC 12 , Saad M 13 , Lee HJ 14 , Kitamura H 15 , Prabhash K 16 , Zou Q 17 , Curigliano G 18 , Poon E 19 , Choo SP 20 , Peters S 21 , Lim E 19 , Yoshino T 22 , Pentheroudakis G 23

Affiliations 

  • 1 Division of Medical Oncology, National Cancer Centre Singapore, Singapore; Oncology Academic Programme, Duke-NUS Medical School, Singapore, Singapore. Electronic address: ravindran.kanesvaran@singhealth.com.sg
  • 2 Department of Medical Oncology, Virgen de la Victoria University Hospital, Institute of Biomedical Research in Málaga, Malaga, Spain
  • 3 Division of Medical Oncology, National University Cancer Institute, Singapore, Singapore
  • 4 Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Saclay, Villejuif, France
  • 5 Oncology Academic Programme, Duke-NUS Medical School, Singapore, Singapore; Division of Radiation Oncology, National Cancer Centre Singapore, Singapore; Division of Medical Sciences, National Cancer Centre Singapore, Singapore, Singapore
  • 6 Department of Urology, Fudan University, Shanghai Cancer Center, Shanghai, China
  • 7 Department of Medical Oncology, Sri Ram Cancer Center, Mahatma Gandhi Medical College Hospital, Mahatma Gandhi University of Medical Sciences & Technology, Jaipur, India
  • 8 Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan
  • 9 Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
  • 10 Department of Radiotherapy and Oncology, Sabah Women and Children's Hospital, Kota Kinabalu, Malaysia
  • 11 Department of Urology, National Taiwan University Hospital, Taipei, Taiwan
  • 12 Division of Clinical Research, Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan; Division of Medical Oncology, Center for Immuno-oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan; National Yang Ming Chiao Tung University School of Medicine, Taipei, Taiwan
  • 13 Department of Clinical Oncology, University of Malaya Medical Centre, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
  • 14 Department of Medical Oncology, Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, South Korea
  • 15 Department of Urology, Faculty of Medicine, University of Toyama, Toyama, Japan
  • 16 Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India
  • 17 Department of Urology, Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China
  • 18 European Institute of Oncology, IRCCS and University of Milano, Milan, Italy
  • 19 Division of Medical Oncology, National Cancer Centre Singapore, Singapore
  • 20 Division of Medical Oncology, National Cancer Centre Singapore, Singapore; Medical Oncology, Curie Oncology, Singapore, Singapore
  • 21 Oncology Department, Lausanne University Hospital (CHUV), Lausanne, Switzerland
  • 22 Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan
  • 23 ESMO, Lugano, Switzerland
ESMO Open, 2022 Aug;7(4):100518.
PMID: 35797737 DOI: 10.1016/j.esmoop.2022.100518

Abstract

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of prostate cancer was published in 2020. It was therefore decided, by both the ESMO and the Singapore Society of Oncology (SSO), to convene a special, virtual guidelines meeting in November 2021 to adapt the ESMO 2020 guidelines to take into account the differences associated with the treatment of prostate cancer in Asia. These guidelines represent the consensus opinions reached by experts in the treatment of patients with prostate cancer representing the oncological societies of China (CSCO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence and was independent of the current treatment practices and drug access restrictions in the different Asian countries. The latter were discussed when appropriate. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with prostate cancer across the different regions of Asia.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications